PDE4B and head and neck squamous cell carcinoma: We also screened for susceptibility between the high-risk and low-risk groups and showed that patients in the high-risk group were more sensitive to talazoparib-1259, camptothecin-1003, vincristine-1818, Azd5991-1720, Teniposide-1809, and Nutlin-3a (-) −1047.Finally, we examined the expression of OLR1, SCN1B and PDE4B genes in HNSCC pathological tissues and validated that these genes could be used to predict the prognosis of HNSCC.